PROTEOMIC ANALYSIS OF CARFILZOMIB (CFZ) RELATED HEART FAILURE IN MULTIPLE MYELOMA (MM) PATIENTS FROM PROSPECTIVE STUDY OF CARDIAC EVENTS DURING PROTEASOME INHIBITOR THERAPY (PROTECT) STUDY

被引：0

作者：

Shabnaz, S. ^{[1
]}

Williams, R. ^{[1
]}

Rubinstein, S. ^{[2
]}

Fradley, M. ^{[3
]}

Baz, R. ^{[4
]}

Pepine, C. ^{[1
]}

Lenihan, D. ^{[5
]}

Cornell, R. ^{[6
]}

Gong, Y. ^{[1
]}

机构：

[1] Univ Florida, Gainesville, FL USA

[2] Univ N Carolina, Chapel Hill, NC USA

[3] Univ Penn, Philadelphia, PA USA

[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[5] St Francis Med Ctr, Cape Girardeau, MO USA

[6] AbbVie, Chicago, IL USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2023年 / 113卷

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

PII-052

引用

页码：S61 / S61

页数：1

共 50 条

[21] Atorvastatin therapy decreases sudden cardiac death in patients with advanced chronic heart failure: a prospective study
Vrtovec, B.
Okrajsek, R.
Golicnik, A.
Ferjan, M.
Starc, V.
Schlegel, T. T.
Radovancevic, R.
Radovancevic, B.
EUROPEAN HEART JOURNAL, 2007, 28 : 520 - 520
[22] Phase I/II Study of Panobinostat and Carfilzomib in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Interim Phase I Safety Analysis
Berdeja, Jesus G.
Hart, Lowell
Lamar, Ruth
Murphy, Patrick
Morgan, Susan
Flinn, Ian W.
BLOOD, 2012, 120 (21)
[23] Health-Related Quality of Life During Carfilzomib-Lenalidomide-Dexamethasone Consolidation: Findings From the Multiple Myeloma CONPET Study
Rosenberg, Tine
Moller, Soren
Abildgaard, Niels
Norgaard, Jakob Nordberg
Lysen, Anna
Tsykonova, Galina
Joao, Cristina
Vangsted, Annette
Schjesvold, Fredrik
Nielsen, Lene Kongsgaard
EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (03) : 517 - 527
[24] UPDATED RESULTS FOR BORTEZOMIB (BTZ)-NAIVE PATIENTS (PTS) ENROLLED IN PX-171-004, AN ONGOING OPEN-LABEL, PHASE (PH) 2 STUDY OF CARFILZOMIB (CFZ), IN RELAPSED MULTIPLE MYELOMA (MM)
Kaufman, J. L.
Vesole, D. H.
Stewart, A.
Jakubowiak, A. J.
Jagannath, S.
Kukreti, V.
Mcdonagh, K. T.
Alsina, M.
Reu, F. J.
Orlowski, R. Z.
Kunkel, L.
Le, M. H.
Vij, R.
Wang, M.
ANNALS OF ONCOLOGY, 2011, 22 : 200 - 201
[25] Healthcare resource utilisation associated with skeletal-related events in European patients with multiple myeloma: Results from a prospective, multinational, observational study
Ashcroft, John
Duran, Ignacio
Hoefeler, Herbert
Lorusso, Vito
Lueftner, Diana
Campioni, Marco
Intorcia, Michele
Bahl, Amit
EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (05) : 479 - 487
[26] Liver stiffness for predicting adverse cardiac events in chinese patients with heart failure: a two-year prospective study
Qian Wang
Yuqing Song
Qiming Wu
Qian Dong
Song Yang
BMC Cardiovascular Disorders, 22
[27] Liver stiffness for predicting adverse cardiac events in chinese patients with heart failure: a two-year prospective study
Wang, Qian
Song, Yuqing
Wu, Qiming
Dong, Qian
Yang, Song
BMC CARDIOVASCULAR DISORDERS, 2022, 22 (01)
[28] A Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Final Analysis of Second Dose Expansion
Berdeja, Jesus G.
Gregory, Tara B.
Faber, Edward
Matous, Jeffrey
Hart, Lowell
Mace, Joseph R.
Arrowsmith, Edward R.
Flinn, Ian W.
BLOOD, 2016, 128 (22)
[29] The nursing role in the management of the novel proteasome inhibitor bortezomib (velcade [™] for injection, formerly PS-341) related gastrointestinal (GI) adverse events (AES) in patients with multiple myeloma (MM).
Lilleby, K
ONCOLOGY NURSING FORUM, 2004, 31 (02) : 403 - 403
[30] A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
Alsina, Melissa
Trudel, Suzanne
Furman, Richard R.
Rosen, Peter J.
O'Connor, Owen A.
Comenzo, Raymond L.
Wong, Alvin
Kunkel, Lori A.
Molineaux, Christopher J.
Goy, Andre
CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4830 - 4840

← 1 2 3 4 5 →